Insitro
Insitro raises $400M Series D at $2.8B valuation
Insitro: Series D Funding Round
Insitro has successfully raised $400M in Series D funding, reaching a valuation of $2.8B.
Company Overview
Machine learning for drug discovery
Funding Details
The Series D round was led by Blackstone, with participation from Canada Pension Plan Investment Board, Arch Venture Partners, Foresite Capital, GV, Andreessen Horowitz.
Company Information
- Headquarters: 279 East Grand Avenue, South San Francisco, CA 94080
- Founded: 2018
- Employees: 300+
- Category: Biotech
Investment
Insitro plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Blackstone: Verified investor in Series D
- Canada Pension Plan Investment Board: Verified investor in Series D
- Arch Venture Partners: Verified investor in Series D
- Foresite Capital: Verified investor in Series D
- GV: Verified investor in Series D
- Andreessen Horowitz: Verified investor in Series D
Company Info
Investors (6)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free